Rotterdam Square hosts interactive session on Financial Dilemmas in the Biotech Landscape

Due to the major role of biotech in Life Sciences & Health and the increasing pressure and demand for new techniques and models, Rotterdam Square hosted a session on biotech and balancing its financial dilemmas on Thursday, April 11, at Erasmus MC.

We would like to thank our guest speakers Robert Al, director of Erasmus MC Technology Transfer Office (TTO), Dirk van Asseldonk, CEO of Erasmus MC spin-off LentiCure, Nettie Buitelaar, CEO of Biotech Booster, and Dirk Vander Mijnsbrugge, director of Pfizer Netherlands for sharing with us how hospitals, business, the pharmaceutical industry and government are working together to solve financial struggles in the biotech industry.

With increasing costs to develop medicines for (rare) diseases, it is clear the biotech industry needs support to bring innovative products to the market. The Netherlands exceeds in science, but can improve in turning science into successful companies and products that reach patients. With research on new business models, the biotech landscape is changing. Transparency, open communication and collaboration with the public sector, for example in public-private partnerships, are the key. This is necessary to prevent difficult ethical questions and cure more (rare) diseases, now and in the future.

We were excited to see the interaction between the speakers and audience. There was a great dynamic with insightful questions and discussions. We would like to thank everyone who joined us, participated in the conversation, and hope you got more connected to the Life Sciences & Health network.

Are you interested in joining one of our upcoming events? Check out our events page or click here to register for our mailing list to automatically stay up-to-date.